SPOTLIGHT -
Moffitt study shows genomic testing can identify African American prostate cancer patients with high-risk disease
Moffitt Cancer Center conducted the first prospective study to investigate genomic biomarkers associated with aggressive disease in African American men with prostate cancer
Moffitt study shows adaptive therapy improves outcomes, reduces care costs for prostate cancer patients
“These analyses illustrate the critical role for inclusion of mathematical models, evolutionary first principles and computer simulations in trial design. Unlike conventional clinical trials, this approach allows both cohort and patient-specific analyses," said Jingsong Zhang, MD, PhD.
Moffitt researchers contribute to discovery of mechanism leading to drug resistance in prostate cancer
The Moffitt research team, in collaboration with scientists at Washington University in St. Louis, wanted to identify alternative resistance mechanisms to enzalutamide and abiraterone in prostate cancer patients.
Moffitt researchers discover new target for CAR T-Cells in solid tumors
Prostate tumors are among the cancers for whom this novel therapy is being explored.